semaglutide patent expiration Ozempic's Protection Starts to Expire in 2026. What Next? What is the patent landscape

Based on data from the phase 2 clinical trial of retatrutide (NCT04881760), published in the New England Journal of Medicine in 2023, gastrointestinal adverse events were among the most frequently reported side effects across all dose groups

Average weight loss Mounjaro and Wegovy both have proven effectiveness at aiding weight loss in clinical trials

Injects weekly

This is why semaglutide, which activates GLP-1 receptors, is associated with improved insulin sensitivity, reduced blood sugar, and decreased energy intake

Regulatory Outlook Weight-loss drugs like retatrutide are already catching the eyes of regulators, doctors, and patients around the world

A number like that raises an obvious question: what does it actually mean for you